Welcome to our dedicated page for Respirerx Pharma news (Ticker: RSPI), a resource for investors and traders seeking the latest updates and insights on Respirerx Pharma stock.
RespireRx Pharmaceuticals Inc. develops drug candidates for disorders linked to disrupted neuronal signaling through the RespireRx Group, including EndeavourRx LLC and ResolutionRx Ltd. Company updates center on licensed and patented compound families, including dronabinol assets for obstructive sleep apnea, GABAkines such as KRM-II-81 for neurological and psychiatric indications, and AMPAkines such as CX1739 for spinal cord injury-related bladder function.
Announcements also cover research publications, government-supported development awards, patent-license agreements, subsidiary organization, private financing efforts, and corporate status matters. The company has disclosed that the SEC revoked the Exchange Act registration of its securities under Section 12(j), making securities-registration status part of its durable public-company history.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announced significant advancements in its drug development programs targeting neurological disorders. The company is preparing to publish a review on its GABAkine compound, KRM-II-81, which shows promise in treating epilepsy, chronic pain, anxiety, and depression. Additionally, ongoing collaborations are expected to enhance AMPAkines for spinal cord injury recovery, and innovative formulations of dronabinol are in preclinical development for obstructive sleep apnea. While progress is noted, key compounds have yet to enter human trials, indicating risk in their future success.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) has successfully up-listed from the OTC Pink Market to the OTCQB Venture Market, effective February 8, 2021. The company's ticker symbol has reverted to RSPI from RSPID. RespireRx focuses on developing innovative treatments for conditions such as obstructive sleep apnea and ADHD, leveraging its two main drug platforms: ResolutionRx (pharmaceutical cannabinoids) and EndeavourRx (neuromodulators). The management is considering separating these platforms into subsidiaries to optimize value and attract funding.
RespireRx Pharmaceuticals has been uplisted from the OTC Pink Market to the OTCQB Venture Market as of February 8, 2021. The ticker symbol has changed back to RSPI from RSPID. The company's focus is on developing treatments for various disorders including obstructive sleep apnea, ADHD, and chronic pain through two main drug platforms: ResolutionRx and EndeavourRx. RespireRx aims to enhance asset value by potentially establishing formal subsidiaries and engaging in strategic partnerships and business development efforts. However, there are no guarantees regarding successful transactions.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announced the publication of a review on CX717, an ampakine that enhances motor nerve function post-spinal cord injury, by Dr. David Fuller. The article in Experimental Neurology highlights CX717's ability to improve phrenic motor nerve activity over 8 weeks, suggesting potential benefits for spinally injured patients. Chief Scientific Officer Arnold Lippa emphasized the intention to advance this research towards human clinical trials, underscoring the company's focus on neuromodulators for treating diverse neurological disorders.